Last reviewed · How we verify
Early Vasopressors
Early vasopressors are sympathomimetic agents that increase blood pressure and tissue perfusion by stimulating adrenergic receptors to counteract hypotension in critically ill patients.
Early vasopressors are sympathomimetic agents that increase blood pressure and tissue perfusion by stimulating adrenergic receptors to counteract hypotension in critically ill patients. Used for Septic shock with hypotension, Cardiogenic shock, Distributive shock requiring hemodynamic support.
At a glance
| Generic name | Early Vasopressors |
|---|---|
| Also known as | Norepinephrine |
| Sponsor | Massachusetts General Hospital |
| Drug class | Sympathomimetic vasopressor |
| Target | Alpha-1 and beta-1 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Intensive Care Medicine |
| Phase | Phase 3 |
Mechanism of action
Vasopressors work by binding to alpha and/or beta-adrenergic receptors on vascular smooth muscle and the heart, causing vasoconstriction and increased cardiac output. This mechanism restores blood pressure and improves organ perfusion in patients experiencing septic shock, cardiogenic shock, or other forms of distributive hypotension. Early administration in sepsis protocols aims to prevent end-organ damage and improve survival outcomes.
Approved indications
- Septic shock with hypotension
- Cardiogenic shock
- Distributive shock requiring hemodynamic support
Common side effects
- Tachycardia
- Arrhythmias
- Hypertension (rebound)
- Tissue necrosis at infusion site
- Decreased renal perfusion
Key clinical trials
- Early Methylene Blue in the Microhemodynamics of Septic Patients (PHASE2, PHASE3)
- Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis (PHASE3)
- Early Versus Late Adjunctive Vasopressin in Septic Shock (PHASE4)
- Implementation of Timely Management of Sepsis and Septic Shock Protocol in the Emergency Department and Intensive Care Unit: A Quality Improvement Project at AFHJ (NA)
- Enteral Versus Parenteral Nutrition During Recovery After Shock (NA)
- Early Vasopressors in Sepsis (PHASE3)
- Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges (PHASE1)
- Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Early Vasopressors CI brief — competitive landscape report
- Early Vasopressors updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI